Min‐Bin Chen
Impact in
- Cancer Research top 5%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Cancer, Hypoxia, and Metabolism
- Oncology top 5%
Papers in
-
- PI3K/AKT/mTOR signaling in cancer 9
- RNA modifications and cancer 7
- Metabolism, Diabetes, and Cancer 6
- Ubiquitin and proteasome pathways 5
- Sphingolipid Metabolism and Signaling 4
- Oncology 20
- Inflammatory Biomarkers in Disease Prognosis 4
- Co-authors
- Pei‐Hua Lu (28 shared papers)Xiao‐Yang Wu (9 shared papers)Mu-Xin Wei (9 shared papers)Chaoying Liu (7 shared papers)Wei Shen (8 shared papers)Li-Na Zhou (12 shared papers)Ping Zeng (10 shared papers)Zhi-qing Zhang (7 shared papers)
- Journals
- Oncotarget (12 papers)PLoS ONE (7 papers)Cell Death and Disease (6 papers)Breast Cancer Research and Treatment (4 papers)Cell Death Discovery (3 papers)
- Partner nations
- ChinaUnited StatesBelgium
In The Last Decade
Min‐Bin Chen
82 papers receiving 2.5k citations
Min‐Bin Chen's Hit Papers
Peers
Comparison fields: 5 of 100
- Cancer Research 542
- Oncology 601
- Molecular Biology 1.3k
- Physiology 50
- Toxicology 36
Countries citing papers authored by Min‐Bin Chen
This map shows the geographic impact of Min‐Bin Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Min‐Bin Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Min‐Bin Chen more than expected).
Fields of papers citing papers by Min‐Bin Chen
This network shows the impact of papers produced by Min‐Bin Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Min‐Bin Chen. The network helps show where Min‐Bin Chen may publish in the future.
Co-authors
The 25 scholars most cited alongside Min‐Bin Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 84 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 121 | |
| 2 | 2011 | 105 | |
| 3 | 2013 | 98 | |
| 4 | 2018 | 93 | |
| 5 | 2013 | 84 | |
| 6 | 2018 | 82 | |
| 7 | 2010 | 79 | |
| 8 | 2018 | 76 | |
| 9 | 2015 | 76 | |
| 10 | Crosstalk between ferroptosis and cuproptosis: From mechanism to potential clinical application Hit paper breakdown → | 2024 | 75 |
| 11 | 2016 | 74 | |
| 12 | 2012 | 71 | |
| 13 | 2015 | 65 | |
| 14 | 2021 | 63 | |
| 15 | 2021 | 56 | |
| 16 | 2017 | 55 | |
| 17 | 2015 | 52 | |
| 18 | 2015 | 49 | |
| 19 | 2017 | 45 | |
| 20 | 2012 | 44 |
About Min‐Bin Chen
Min‐Bin Chen is a scholar working on Molecular Biology, Oncology, Cancer Research, Pulmonary and Respiratory Medicine and Surgery, having authored 84 papers that have together received 2.5k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (9 papers), RNA modifications and cancer (7 papers), Metabolism, Diabetes, and Cancer (6 papers), Cancer-related molecular mechanisms research (6 papers), Ubiquitin and proteasome pathways (5 papers), Sphingolipid Metabolism and Signaling (4 papers), Inflammatory Biomarkers in Disease Prognosis (4 papers) and Cancer, Hypoxia, and Metabolism (4 papers). The work is most often cited by research in Cancer Research (542 citations), Oncology (601 citations), Molecular Biology (1.3k citations), Physiology (50 citations) and Toxicology (36 citations). Min‐Bin Chen has collaborated with scholars based in China, United States and Belgium. Frequent co-authors include Pei‐Hua Lu, Xiao‐Yang Wu, Mu-Xin Wei, Chaoying Liu, Wei Shen, Li-Na Zhou, Ping Zeng, Zhi-qing Zhang, Wenxiang Shen and Jin‐Hua Gu. Their work appears in journals such as Oncotarget, PLoS ONE, Cell Death and Disease, Breast Cancer Research and Treatment and Cell Death Discovery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.